Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 11/20 | 0.56 |
| ▸ | WNT1 | P04628 | 9/20 | 0.56 |
| ▸ | AURKA | O14965 | 3/20 | 0.48 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | RHEB | Q15382 | 1/20 | 0.43 |
| ▸ | CLK2 | P49760 | 3/20 | 0.41 |
| ▸ | CLK3 | P49761 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30633374 | 1.00 | DYRK1A (0.56) | DYRK1AWNT1AURKAAURKBKDM4E | |
| SCHEMBL31240454 | 0.87 | DYRK1A (0.54) | DYRK1AWNT1PARP1CLK2CLK3 | |
| SCHEMBL26685908 | 0.87 | NUDT1 (0.49) | DYRK1AWNT1NUDT1CLK2CLK3 | |
| SCHEMBL31240736 | 0.87 | NUDT1 (0.49) | DYRK1AWNT1NUDT1CLK2CLK3 | |
| SCHEMBL26686398 | 0.85 | AURKA (0.44) | DYRK1AWNT1AURKAAURKBKDM4E | |
| SCHEMBL30633364 | 0.85 | AURKA (0.44) | DYRK1AWNT1AURKAAURKBKDM4E | |
| SCHEMBL31240633 | 0.84 | CCNK (0.54) | DYRK1AWNT1KDM4ENUDT1CLK2 | |
| SCHEMBL26686484 | 0.84 | CCNK (0.54) | DYRK1AWNT1KDM4ENUDT1CLK2 | |
| SCHEMBL30633128 | 0.83 | CCNK (0.55) | DYRK1AWNT1NUDT1 | |
| SCHEMBL30633338 | 0.83 | NUDT1 (0.48) | DYRK1AWNT1NUDT1GSK3BCLK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | claimed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | claimed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | claimed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023218201-A1 | IKK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | DYRK1A 707/4885WNT1 628/4885AURKA 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.